AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Biomedicine and Engineering Article
PDF (607.1 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Research and Development of Nanopharmaceuticals in China

Research Center of New Drug Evaluation, The State Key Laboratories of Pharmacodynamics and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China
Research Center of Biological Evaluation of Nanopharmaceuticals, China National Academy of Nanotechnology and Engineering, Tianjin 300457, China
Show Author Information

Abstract

Nanopharmacoeuticals based on nanomaterials and nanotechnology are medicinal products for drug delivery, nano drugs and nano therapies, in vivo imaging, in vitro diagnostics, biomaterials, and active implants. Nanoscience and nanotechnology in China become ever more consequential in our lives; all members of the scientific community should better inform and educate the public about the great changes this new nano era is likely to bring. Here we review some main advances on the research and development of nanomaterials, nanotechnology and nanopharmaceuticals in China. For nanopharmaceuticals, we focus on the research and application of nanotechnology in anti-cancer drugs, and biological evaluation studies of nanomaterials.

Keywords

NanomaterialsNanotechnologyChinaNanopharmacoeuticalsResearch

References

[1]

Foldvari M. Nanomedicine research in Canada. Nanomedicine 2006; 2(4): 296
Crossref Google Scholar
[2]

Zhao XJ. Nanomedicine Research in China. Nanomedicine 2006; 2(4): 297
Crossref Google Scholar
[3]

Wong K. Development of nanomedicine in Hong Kong. Nanomedicine 2006; 2(4): 297
Crossref Google Scholar
[4]

Jain NK. Status of nanomedicine research in India. Nanomedicine 2006; 2(4): 297
Crossref Google Scholar
[5]

Urisu T, Wei CM. America—Japan Nanomedicine Society (AJNS). Nanomedicine 2006; 2(4): 297-298
Crossref Google Scholar
[6]

Lee YS. Current research status of biomedical micro and nano technologies in Korea. Nanomedicine 2006; 2(4): 298
Crossref Google Scholar
[7]

Yaminsky I. Outlook into the nanomedicine research in Russia. Nanomedicine 2006; 2(4): 298
Crossref Google Scholar
[8]

Yun J. Singapore — an ideal R&D hub for bionanotechnology. Nanomedicine 2006; 2(4): 299
Crossref Google Scholar
[9]

Hunziker P. Nanomedicine Research in Switzerland. Nanomedicine 2006; 2(4): 299
Crossref Google Scholar
[10]

Donald A. Tomalia. International report on nanomedicine in the U.S.A. Nanomedicine 2006; 2(4): 299
Crossref Google Scholar
[11]

Liang XJ, Chen C, Zhao Y, Jia L, Wang PC. Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr. Drug Meta. 2008; 9(8):697-709. doi:10.2174/138920008786049230
Crossref Google Scholar
[12]

Si DY, Sun YD, Cheng TF, Liu CX. Biomedical evaluation of nanomedicines, Asian J. Pharmacodyn Pharmacokinet, 2007, 7(2):83-97
Google Scholar
[13]

Sun YD, Chen ZM, Wei H, Liu CX. Nanotechnology challenge: safety of nanomaterials and nanomedicines. Asian J. Pharmacodyn Pharmacokinet 2007; 7(1): 17-31.
Google Scholar
[14]

Cheng TF, Sun YD, Si DY, Liu CX. Attention on research of pharmacology and toxicology of nanomedicines. Asian J. Pharmacodyn Pharmacokinet 2009; 9(1):25-27.
Google Scholar
[15]

Bai CL. Ascent of Nanoscience in China. Science 2005; 309: 61-63. doi:10.1126/science.1115172
Crossref Google Scholar
[16]

Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol. Biol. 2010; 596:467-88. doi:10.1007/978-1-60761-416-6_21
Crossref Google Scholar
[17]

Liang F, Chen B.A Review on Biomedical Applications of Single-Walled Carbon Nanotubes. Curr. Med. Chem. 2009 Nov 24. [Epub ahead of print]
Crossref Google Scholar
[18]

Jia X, Fan H, Zhang F, Qin L. Using sonochemistry for the fabrication of hollow ZnO microspheres. Ultrason Sonochem 2010; 17(2): 284-7. doi:10.1016/j.ultsonch.2009.09.010
Crossref Google Scholar
[19]

Ting G, Chang CH, Wang HE. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy.Anticancer Res. 2009; 29(10):4107-18.
Google Scholar
[20]

Li L, Liu J, Diao Z, Shu D, Guo P, Shen G. Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells. Mo.l Biosyst. 2009; 5(11):1361-8. doi:10.1039/b903428e
Crossref Google Scholar
[21]

Liu L, Zhang J, Su X, Mason RP. In vitro and In vivo Assessment of CdTe and CdHgTe Toxicity and Clearance. J. Biomed. Nanotechnol. 2008; 4(4): 524-528. doi:10.1166/jbn.2008.018
Crossref Google Scholar
[22]

Wang Y, Tu SL, Li RS, Yang XY, Liu LR, Zhang QQ. Cholesterol succinyl chitosan anchored liposomes: preparation, characterization, physical stability, and drug release behavior. Nanomedicine 2009 Oct 2.
Crossref Google Scholar
[23]

Gao J. MRI-Visible Micellar Nanomedicine for Targeted Drug Delivery to Lung Cancer Cells. Mol. Pharm. 2009 Aug 26.
Google Scholar
[24]

Huang H, Chen M, Bruno P, Lam R, Robinson E, Gruen D, Ho D. Ultrananocrystalline diamond thin films functionalized with therapeutically active collagen networks. J. Phys. Chem. B 2009; 113(10):2966-71. doi:1 0.1021/jp9004086
Crossref Google Scholar
[25]

Fitzpatrick JM. The application of nanotechnology for the treatment of metastatic prostate cancer. BJU Int. 2009; 104(6).
Google Scholar
[26]

Xia T, Li N, Nel AE. Potential health impact of nanoparticles. Annu. Rev. Public Health. 2009; 30:137-50. doi:10.1146/annurev.publhealth.031308.100155
Crossref Google Scholar
[27]

Xiao Q, Zhou B, Huang S, Tian F, Guan H, Ge Y, Liu X, He Z, Liu Y. Direct observation of the binding process between protein and quantum dots by in situ surface plasmon resonance measurements. Nanotechnology 2009; 20(32): 325101. doi:10.1088/0957-4484/20/32/325101
Crossref Google Scholar
[28]

Li N, Xia T, Nel AE. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic. Biol. Med. 2008; 44(9):1689-99. doi:10.1016/j.freeradbiomed.2008.01.028
Crossref Google Scholar
[29]

Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008; 49(s2):113s-128s. doi:10.2967/jnumed.107.045922
Crossref Google Scholar
[30]

Liang XJ, Chen C, Zhao Y, Jia L, Wang PC. Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr. Drug Metab. 2008; 9(8):697-709. doi:10.2174/138920008786049230
Crossref Google Scholar
[31]

Liu L, Zhang J, Su X, Mason RP.In vitro and In vivo Assessment of CdTe and CdHgTe Toxicity and Clearance. J. Biomed. Nanotechnol. 2008; 4(4):524-528. doi:10.1166/jbn.2008.018
Crossref Google Scholar
[32]

Yin JJ, Lao F, Meng J, Fu PP, Zhao Y, Xing G, Gao X, Sun B, Wang PC, Chen C, Liang XJ. Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol. Pharmacol. 2008; 74(4):1132-40. doi:10.1124/mol.108.048348
Crossref Google Scholar
[33]

Tao SL, Desai TA. Microfabricated drug delivery systems: from particles to pores. Adv. Drug Delivery. Rev. 2003; 55:315-28. doi:10.1016/S0169-409X(02)00227-2
Crossref Google Scholar
[34]
Zhang MJ, Tarn TJ, Xi N. Micro-/nano-devices for controlled drug delivery. Proceedings of the 2004 IEEE International Conference on Robotics and Automation; 2004 April 26-May 1; New Orleans, La. New Orleans. The Conference; 2004; 2068-73.
[35]

Krukemeyer MG, Wagne W, Jakobs M, Kren V. Tumor regression by means of magnetic drug targeting. Nanomedicine 2009; 4(8): 875-882. doi:10.2217/nnm.09.73
Crossref Google Scholar
[36]

Tong L, Zhao Y, Huff T, Hansen M, Wei A, Cheng J. Gold Nanorods Mediate Tumor Cell Death by Compromising Membrane Integrity. Adv. Mater. 2007; 19: 3136–3141. doi:10.1002/adma.200701974
Crossref Google Scholar
[37]

Li Z, Huang P, Zhang X, Lin J, Yang S, Liu B, Gao F, Xi P, Ren QS, Cui DX. RGD-conjugated dendrimer-modified gold nanorods for in Vivo tumor targeting and photothermal therapy. Mol. Pharm. 2010; doi:10.1021/mp9001415
Crossref Google Scholar
[38]

Pan B, Ao L, Gao F, Tian H, He R, Cui D. End-to-end selfassembly and colorimetric characterization of gold nanorods and nanospheres via oligonucleotide hybridization. Nanotechnology 2005; 16:1776–1780. doi:10.1088/0957-4484/16/9/061
Crossref Google Scholar
[39]

Pan B; Cui D; Sheng Y; Ozkan C, Gao F, He R, Li Q.; Xu P, Huang T. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007; 67: 8156–8163. doi:10.1158/0008-5472.CAN-06-4762
Crossref Google Scholar
[40]

Cai W, Chen X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat. Protoc. 2008; 3: 89–96. doi:10.1038/nprot.2007.478
Crossref Google Scholar
[41]

Song H, He R, Wang K, Ruan J, Bao CC, Li N, Ji JJ, Cui DX. Anti-HIF-1a antibody-conjugated pluronic triblock copolymers encapsulated with Paclitaxel for tumor targeting therapy. Biomaterials 2009, doi:10.1016/j.bio materials.2009.11.067
Crossref Google Scholar
[42]

Chen Z, Chen H, Meng H, Xing G, Gao X, Sun B, Shi X, Yuan H, Zhang C, Liu R, Zhao F, Zhao Y, Fang X. Biodistribution and metabolic paths of silica coated CdSeS quantum dots. Toxicol. Appl. Pharmacol. 2008; 230(3):364-71. doi:10.1016/j.taap.2008.03.022
Crossref Google Scholar
[43]

Tang N, Du G, Wang N, Liu C, Hang H, and Liang W. Improving Penetration in Tumors with Nano- assemblies of Phospholipids and Doxorubicin. J. Natl. Cancer Inst. 2007; 99: 1004-1015. doi:10.1093/jnci/djm027
Crossref Google Scholar
[44]

Dreher MR, Chilkoti A. Toward a Systems Engineering Approach to Cancer Drug Delivery. J. Natl. Cancer Inst. 2007; 99: 983-985. doi:10.1093/jnci/djm042
Crossref Google Scholar
[45]

Wei G, Xiao S, Si D, Liu C. Comparative pharmacokinetics of micelle- or liposomal encapsulated doxorubicin formulations to healthy rats and tumor-bearing mice. Drug Metabolism Reviews 2008; 40(S2):81-82.
Google Scholar
[46]

Xu Y, Xiao S, Wei G, Liu C, Si D. Nanoparticle of doxorubicin eliminate the accumulation in tissues of tumorbearing mice. Drug Metabolism Reviews 2008; 40(S2):193.
Google Scholar
[47]

Cheng T, Si D, Liu C. Rapid and sensitive LC-MS method for pharmacokinetic study of vinorelbine in rats. Biomedical Chromatography, 2009; 23:909-911. doi:10.1002/bmc.1216
Crossref Google Scholar
[48]

Zhang J, Zhang Z, Yang H, Tan Q, Qin S, Qiu X. Lyophilized Paclitaxel Magnetoliposomes as a Potential Drug Delivery System for Breast Carcinoma via Parenteral Administration: In Vitro and in Vivo Studies. Pharmaceutical Research 2005; 22(4):573-583. doi:10.1007/s11095-005-2496-8
Crossref Google Scholar
[49]

Li Q, Cheng T, Huang Y, Si D, Liu C. Comparative pharmacokinetics and tissue distribution between free and Micelle-Encapsulated Alprostadil. Drug Metabolism Reviews, 2008; 40(S2):80-81.
Google Scholar
[50]

Thomas T, Thomas K, Sadrich N, Savage N, Adair P, Bronaugh R. Research strategies for safety evaluation of nanomaterials, Part Ⅶ: Evaluating consumer exposure to nanoscale materials. Toxicol. Sci. 2006; 91(1):14-19. doi:10.1093/toxsci/kfj129
Crossref Google Scholar
[51]

Gubbels-van Hal WMLG, Blaauboer BJ, Barentsen HM, Hoitink MA, Meerts IATM, van der Hoeven JCM. An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing. Reg. Toxicol. Pharmacol. 2005; 42:284–295. doi:10.1016/j.yrtph.2005.05.002
Crossref Google Scholar
[52]

Cui D, Gao H. Advance and prospect of bionanomaterials. Biotechnol. Prog. 2003; 19:683-692. doi:10.1021/bp025791i
Crossref Google Scholar
Nano Biomedicine and Engineering
Volume 1 Issue 1,
March 2009
Pages 1-12
DOI: 10.5101/nbe.v1i1.p1-12
Cite this article:
Liu C. Research and Development of Nanopharmaceuticals in China. Nano Biomedicine and Engineering, 2009, 1(1): 1-12. https://doi.org/10.5101/nbe.v1i1.p1-12

368

Views

14

Downloads

4

Crossref

35

Scopus

Altmetrics
Received: 10 November 2009
Accepted: 06 December 2009
Published: 09 December 2009
© 2009 C. Liu et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Return